ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2021 (Unaudited)
Description | Shares | Fair Value | ||||||
COMMON STOCK — 99.8% | ||||||||
Australia — 1.0% | ||||||||
Health Care — 1.0% | ||||||||
CSL | 10,907 | $ | 2,316,249 | |||||
Total Australia | 2,316,249 | |||||||
Belgium — 0.6% | ||||||||
Information Technology — 0.6% | ||||||||
Materialise ADR * | 66,865 | 1,455,651 | ||||||
Total Belgium | 1,455,651 | |||||||
China — 1.1% | ||||||||
Health Care — 1.1% | ||||||||
Ping An Healthcare and Technology * (A) | 278,900 | 2,601,947 | ||||||
Total China | 2,601,947 | |||||||
Denmark — 0.8% | ||||||||
Health Care — 0.8% | ||||||||
GN Store Nord | 22,978 | 2,013,217 | ||||||
Total Denmark | 2,013,217 | |||||||
France — 2.5% | ||||||||
Health Care — 2.5% | ||||||||
Cellectis ADR * | 225,462 | 2,919,733 | ||||||
Eurofins Scientific | 24,778 | 2,962,865 | ||||||
Total Health Care | 5,882,598 | |||||||
Total France | 5,882,598 | |||||||
Germany — 1.5% | ||||||||
Health Care — 1.5% | ||||||||
Siemens Healthineers (A) | 55,203 | 3,644,808 | ||||||
Total Germany | 3,644,808 | |||||||
Hong Kong — 1.5% | ||||||||
Health Care — 1.5% | ||||||||
Alibaba Health Information Technology * | 1,022,000 | 1,588,656 | ||||||
JD Health International * (A) | 187,100 | 2,009,149 | ||||||
Total Health Care | 3,597,805 | |||||||
Total Hong Kong | 3,597,805 | |||||||
Italy — 1.6% | ||||||||
Health Care — 1.6% | ||||||||
DiaSorin | 18,295 | 3,712,975 | ||||||
Total Italy | 3,712,975 | |||||||
Japan — 0.7% | ||||||||
Health Care — 0.7% | ||||||||
Terumo | 43,600 | 1,683,218 | ||||||
Total Japan | 1,683,218 | |||||||
Netherlands — 0.9% | ||||||||
Health Care — 0.9% | ||||||||
Koninklijke Philips | 49,602 | 2,287,441 | ||||||
Total Netherlands | 2,287,441 | |||||||
Switzerland — 4.1% | ||||||||
Health Care — 4.1% | ||||||||
Lonza Group | 4,391 | 3,416,676 | ||||||
Roche Holding | 7,324 | 2,831,252 | ||||||
Tecan Group | 5,942 | 3,425,681 | ||||||
Total Health Care | 9,673,609 | |||||||
Total Switzerland | 9,673,609 | |||||||
United Kingdom — 1.7% | ||||||||
Health Care — 1.7% | ||||||||
EMIS Group | 99,272 | 1,780,503 | ||||||
Smith & Nephew PLC | 107,103 | 2,177,084 | ||||||
Total Health Care | 3,957,587 | |||||||
Total United Kingdom | 3,957,587 | |||||||
United States — 81.8% | ||||||||
Health Care — 79.3% | ||||||||
1Life Healthcare * | 82,898 | 2,241,562 | ||||||
Abbott Laboratories | 19,494 | 2,358,384 | ||||||
ABIOMED * | 11,320 | 3,703,225 | ||||||
Agilent Technologies | 19,018 | 2,914,128 | ||||||
Align Technology * | 4,555 | 3,169,369 | ||||||
Alnylam Pharmaceuticals * | 11,256 | 2,014,149 | ||||||
Arrowhead Pharmaceuticals * | 21,524 | 1,491,398 | ||||||
Avanos Medical * | 50,671 | 1,922,458 | ||||||
Axogen * | 172,718 | 3,518,266 | ||||||
Baxter International | 25,306 | 1,957,419 | ||||||
Becton Dickinson | 7,489 | 1,915,312 | ||||||
BioMarin Pharmaceutical * | 28,619 | 2,195,936 | ||||||
Bio-Rad Laboratories, Cl A * | 4,849 | 3,585,884 | ||||||
Boston Scientific * | 77,992 | 3,556,435 | ||||||
Bristol-Myers Squibb | 31,045 | 2,107,024 | ||||||
Cardiovascular Systems * | 81,695 | 3,291,492 | ||||||
CareDx * | 38,070 | 3,199,403 | ||||||
Catalent * | 28,188 | 3,377,204 | ||||||
Cerus * | 358,461 | 1,806,643 | ||||||
Charles River Laboratories International * | 9,728 | 3,958,518 | ||||||
Codexis * | 122,852 | 2,599,548 | ||||||
CONMED | 15,071 | 2,078,894 | ||||||
CryoLife * | 95,314 | 2,573,478 | ||||||
Danaher | 13,187 | 3,923,000 | ||||||
DexCom * | 8,557 | 4,411,218 | ||||||
Editas Medicine, Cl A * | 97,359 | 4,075,448 | ||||||
Edwards Lifesciences * | 25,129 | 2,821,233 | ||||||
Exact Sciences * | 28,231 | 3,044,431 |
ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2021 (Unaudited)
Description | Shares | Fair Value | ||||||
Fulgent Genetics * | 40,892 | $ | 3,772,287 | |||||
Glaukos * | 44,508 | 2,269,908 | ||||||
Globus Medical, Cl A * | 24,001 | 1,996,163 | ||||||
Health Catalyst * | 57,952 | 3,364,693 | ||||||
Hologic * | 41,031 | 3,078,966 | ||||||
Illumina * | 7,839 | 3,886,184 | ||||||
Incyte * | 36,188 | 2,799,142 | ||||||
Insulet * | 12,058 | 3,372,502 | ||||||
Integra LifeSciences Holdings * | 48,520 | 3,512,363 | ||||||
Intuitive Surgical * | 3,938 | 3,904,369 | ||||||
Invitae * | 90,990 | 2,546,810 | ||||||
IQVIA Holdings * | 12,753 | 3,158,918 | ||||||
iRhythm Technologies * | 50,684 | 2,590,966 | ||||||
Masimo * | 11,407 | 3,107,153 | ||||||
Medpace Holdings * | 15,497 | 2,726,542 | ||||||
Moderna * | 7,950 | 2,811,120 | ||||||
NanoString Technologies * | 46,706 | 2,892,970 | ||||||
Natera * | 33,619 | 3,850,048 | ||||||
NeoGenomics * | 73,736 | 3,399,230 | ||||||
Nevro * | 18,507 | 2,868,585 | ||||||
Novocure * | 7,963 | 1,226,382 | ||||||
Omnicell * | 21,137 | 3,096,571 | ||||||
Penumbra * | 11,669 | 3,106,638 | ||||||
PerkinElmer | 19,461 | 3,546,378 | ||||||
Quidel * | 26,300 | 3,720,661 | ||||||
Regeneron Pharmaceuticals * | 5,889 | 3,383,878 | ||||||
STAAR Surgical * | 11,929 | 1,525,958 | ||||||
Stryker | 9,828 | 2,662,798 | ||||||
Tabula Rasa HealthCare * | 73,941 | 3,176,505 | ||||||
Tactile Systems Technology * | 49,819 | 2,440,135 | ||||||
Teladoc Health * | 11,178 | 1,659,374 | ||||||
Thermo Fisher Scientific | 7,302 | 3,943,153 | ||||||
Veeva Systems, Cl A * | 5,683 | 1,890,791 | ||||||
Veracyte * | 99,518 | 4,434,522 | ||||||
Vertex Pharmaceuticals * | 11,709 | 2,360,300 | ||||||
Vocera Communications * | 94,180 | 3,951,792 | ||||||
187,846,214 | ||||||||
Information Technology — 2.5% | ||||||||
3D Systems * | 67,204 | 1,850,798 | ||||||
Brooks Automation | 23,644 | 2,104,552 | ||||||
Novanta * | 13,533 | 1,900,169 | ||||||
5,855,519 | ||||||||
Total United States | 193,701,733 | |||||||
Total Common Stock | ||||||||
(Cost $222,727,369) | 236,528,838 | |||||||
SHORT-TERM INVESTMENT — 0.2% | ||||||||
Invesco Government & Agency, Cl Institutional, 0.03%(B) | 475,887 | 475,887 | ||||||
Total Short-Term Investment | ||||||||
(Cost $475,887) | 475,887 | |||||||
Total Investments - 100.0% | ||||||||
(Cost $223,203,256) | $ | 237,004,725 |
Percentages based on Net Assets of $236,945,109.
* | Non-income producing security. |
(A) | Securities sold within terms of a private placement memorandum, exempt from registration under Section 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “accredited investors.” These securities have been determined to be liquid under guidelines established by the board of Trustees. As of July 31, 2021, the value of these securities amounted to $8,255,904, representing 3.5% of the Net Assets of the Fund. |
(B) | Rate shown is the 7-day effective yield as of July 31, 2021. |
ADR – American Depository Receipt
Cl – Class
PLC - Public Limited Company
As of July 31, 2021, all of the Fund's investments were considered Level 1 of the fair value hierarchy, in accordance with the authoritative guidance under U.S. GAAP.
For the period ended July 31, 2021, there were no transfers in or out of Level 3.
For information regarding the Trust's policy regarding valuation of investments and other significant accounting policies, please refer to the Trust's most recent semi-annual and annual financial statements.
ROB-QH-001-1600